ReNAgade NEWS & PRESS RELEASES

We’re rapidly and relentlessly advancing transformational RNA medicines.

See the headlines our progress has inspired.

April 2024

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology

Read More
April 2024

ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting

Read More
February 2024

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Read More
February 2024

Evercore ISI 2024 Emerging Biotech Conference Webcast

Read More
February 2024

ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference

Read More
January 2024

ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference

Read More
December 2023

ReNAgade Therapeutics Appoints Paul Perreault to Board of Directors

Read More
October 2023

ReNAgade Therapeutics to Present Preclinical Data Demonstrating Potent Extra-Hepatic Delivery of mRNA Using Proprietary Lipid Nanoparticles at 11th International mRNA Health Conference

Read More
September 2023

ReNAgade Therapeutics Named to the 2023 Endpoints 11

Read More
September 2023

ReNAgade Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Read More

“RNA without limits”, “Deliver-Code-Edit-Insert” are trademarks of ReNAgade Therapeutics, Inc.